Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases

J. E. Gottenberg; L. Guillevin; O. Lambotte; B. Combe; Y. Allanore; A. Cantagrel; C. Larroche; M. Soubrier; L. Bouillet; M. Dougados; O. Fain; D. Farge; X. Kyndt; O. Lortholary; C. Masson; B. Moura; P. Remy; T. Thomas; D. Wendling; J. M. Anaya; J. Sibilia; Xavier Mariette

doi:10.1136/ard.2004.029694

Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases

J. E. Gottenberg, L. Guillevin, O. Lambotte, B. Combe, Y. Allanore, A. Cantagrel, C. Larroche, M. Soubrier, L. Bouillet, M. Dougados, O. Fain, D. Farge, X. Kyndt, O. Lortholary, C. Masson, B. Moura, P. Remy, T. Thomas, D. Wendling, J. M. AnayaJ. Sibilia, Xavier Mariette

Research output: Contribution to journal › Article › peer-review

365 Scopus citations

Abstract

Objective: To assess the tolerance and efficacy of rituximab in patients with various autoimmune diseases seen in daily rheumatological practice. Methods: 866 rheumatology and internal medicine practitioners were contacted by email to obtain the files of patients treated with rituximab for systemic autoimmune diseases. Patients with lymphoma were analysed if the evolution of the autoimmune disease could be evaluated. Results: In all, 43 of 49 cases could be analysed, including 14 with rheumatoid arthritis (RA), 13 with systemic lupus erythematosus (SLE), six with primary Sjögren's syndrome (pSS), five with systemic vasculitis, and five with other autoimmune diseases. Rituximab was prescribed for lymphoma in two patients with RA and two with pSS. In the 39 other cases, rituximab was given because of the refractory character of the autoimmune disease. The mean follow up period was 8.3 months (range 2 to 26). There were 11 adverse events in 10 patients and treatment had to be discontinued in six. Efficacy was observed in 30 patients (70%): RA 11, SLE 9, pSS 5, vasculitis 2, antisynthetase syndromes 2, sarcoidosis 1. The mean decrease in corticosteroid intake was 9.5 mg/d (range 0 to 50) in responders. Seven patients experienced relapse after mean 8.1 months (5 to 15). Three patients died because of refractory autoimmune disease. Conclusions: Despite absence of marketing authorisation, rituximab is used to treat various refractory autoimmune diseases in daily rheumatological practice. This study showed good tolerance and short term clinical efficacy, with marked corticosteroid reduction in patients with SLE, pSS, vasculitis, and polymyositis.

Original language	English (US)
Pages (from-to)	913-920
Number of pages	8
Journal	Annals of the Rheumatic Diseases
Volume	64
Issue number	6
DOIs	https://doi.org/10.1136/ard.2004.029694
State	Published - Jun 2005
Externally published	Yes

All Science Journal Classification (ASJC) codes

Immunology and Allergy
Rheumatology
Immunology
General Biochemistry, Genetics and Molecular Biology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1136/ard.2004.029694

Cite this

Gottenberg, J. E., Guillevin, L., Lambotte, O., Combe, B., Allanore, Y., Cantagrel, A., Larroche, C., Soubrier, M., Bouillet, L., Dougados, M., Fain, O., Farge, D., Kyndt, X., Lortholary, O., Masson, C., Moura, B., Remy, P., Thomas, T., Wendling, D., ... Mariette, X. (2005). Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Annals of the Rheumatic Diseases, 64(6), 913-920. https://doi.org/10.1136/ard.2004.029694

@article{f885b37dda554507a1eda3bdffe8697b,

title = "Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases",

abstract = "Objective: To assess the tolerance and efficacy of rituximab in patients with various autoimmune diseases seen in daily rheumatological practice. Methods: 866 rheumatology and internal medicine practitioners were contacted by email to obtain the files of patients treated with rituximab for systemic autoimmune diseases. Patients with lymphoma were analysed if the evolution of the autoimmune disease could be evaluated. Results: In all, 43 of 49 cases could be analysed, including 14 with rheumatoid arthritis (RA), 13 with systemic lupus erythematosus (SLE), six with primary Sj{\"o}gren's syndrome (pSS), five with systemic vasculitis, and five with other autoimmune diseases. Rituximab was prescribed for lymphoma in two patients with RA and two with pSS. In the 39 other cases, rituximab was given because of the refractory character of the autoimmune disease. The mean follow up period was 8.3 months (range 2 to 26). There were 11 adverse events in 10 patients and treatment had to be discontinued in six. Efficacy was observed in 30 patients (70%): RA 11, SLE 9, pSS 5, vasculitis 2, antisynthetase syndromes 2, sarcoidosis 1. The mean decrease in corticosteroid intake was 9.5 mg/d (range 0 to 50) in responders. Seven patients experienced relapse after mean 8.1 months (5 to 15). Three patients died because of refractory autoimmune disease. Conclusions: Despite absence of marketing authorisation, rituximab is used to treat various refractory autoimmune diseases in daily rheumatological practice. This study showed good tolerance and short term clinical efficacy, with marked corticosteroid reduction in patients with SLE, pSS, vasculitis, and polymyositis.",

author = "Gottenberg, {J. E.} and L. Guillevin and O. Lambotte and B. Combe and Y. Allanore and A. Cantagrel and C. Larroche and M. Soubrier and L. Bouillet and M. Dougados and O. Fain and D. Farge and X. Kyndt and O. Lortholary and C. Masson and B. Moura and P. Remy and T. Thomas and D. Wendling and Anaya, {J. M.} and J. Sibilia and Xavier Mariette",

year = "2005",

month = jun,

doi = "10.1136/ard.2004.029694",

language = "English (US)",

volume = "64",

pages = "913--920",

journal = "Annals of the Rheumatic Diseases",

issn = "0003-4967",

publisher = "BMJ Publishing Group",

number = "6",

}

Gottenberg, JE, Guillevin, L, Lambotte, O, Combe, B, Allanore, Y, Cantagrel, A, Larroche, C, Soubrier, M, Bouillet, L, Dougados, M, Fain, O, Farge, D, Kyndt, X, Lortholary, O, Masson, C, Moura, B, Remy, P, Thomas, T, Wendling, D, Anaya, JM, Sibilia, J & Mariette, X 2005, 'Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases', Annals of the Rheumatic Diseases, vol. 64, no. 6, pp. 913-920. https://doi.org/10.1136/ard.2004.029694

TY - JOUR

T1 - Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases

AU - Gottenberg, J. E.

AU - Guillevin, L.

AU - Lambotte, O.

AU - Combe, B.

AU - Allanore, Y.

AU - Cantagrel, A.

AU - Larroche, C.

AU - Soubrier, M.

AU - Bouillet, L.

AU - Dougados, M.

AU - Fain, O.

AU - Farge, D.

AU - Kyndt, X.

AU - Lortholary, O.

AU - Masson, C.

AU - Moura, B.

AU - Remy, P.

AU - Thomas, T.

AU - Wendling, D.

AU - Anaya, J. M.

AU - Sibilia, J.

AU - Mariette, Xavier

PY - 2005/6

Y1 - 2005/6

N2 - Objective: To assess the tolerance and efficacy of rituximab in patients with various autoimmune diseases seen in daily rheumatological practice. Methods: 866 rheumatology and internal medicine practitioners were contacted by email to obtain the files of patients treated with rituximab for systemic autoimmune diseases. Patients with lymphoma were analysed if the evolution of the autoimmune disease could be evaluated. Results: In all, 43 of 49 cases could be analysed, including 14 with rheumatoid arthritis (RA), 13 with systemic lupus erythematosus (SLE), six with primary Sjögren's syndrome (pSS), five with systemic vasculitis, and five with other autoimmune diseases. Rituximab was prescribed for lymphoma in two patients with RA and two with pSS. In the 39 other cases, rituximab was given because of the refractory character of the autoimmune disease. The mean follow up period was 8.3 months (range 2 to 26). There were 11 adverse events in 10 patients and treatment had to be discontinued in six. Efficacy was observed in 30 patients (70%): RA 11, SLE 9, pSS 5, vasculitis 2, antisynthetase syndromes 2, sarcoidosis 1. The mean decrease in corticosteroid intake was 9.5 mg/d (range 0 to 50) in responders. Seven patients experienced relapse after mean 8.1 months (5 to 15). Three patients died because of refractory autoimmune disease. Conclusions: Despite absence of marketing authorisation, rituximab is used to treat various refractory autoimmune diseases in daily rheumatological practice. This study showed good tolerance and short term clinical efficacy, with marked corticosteroid reduction in patients with SLE, pSS, vasculitis, and polymyositis.

AB - Objective: To assess the tolerance and efficacy of rituximab in patients with various autoimmune diseases seen in daily rheumatological practice. Methods: 866 rheumatology and internal medicine practitioners were contacted by email to obtain the files of patients treated with rituximab for systemic autoimmune diseases. Patients with lymphoma were analysed if the evolution of the autoimmune disease could be evaluated. Results: In all, 43 of 49 cases could be analysed, including 14 with rheumatoid arthritis (RA), 13 with systemic lupus erythematosus (SLE), six with primary Sjögren's syndrome (pSS), five with systemic vasculitis, and five with other autoimmune diseases. Rituximab was prescribed for lymphoma in two patients with RA and two with pSS. In the 39 other cases, rituximab was given because of the refractory character of the autoimmune disease. The mean follow up period was 8.3 months (range 2 to 26). There were 11 adverse events in 10 patients and treatment had to be discontinued in six. Efficacy was observed in 30 patients (70%): RA 11, SLE 9, pSS 5, vasculitis 2, antisynthetase syndromes 2, sarcoidosis 1. The mean decrease in corticosteroid intake was 9.5 mg/d (range 0 to 50) in responders. Seven patients experienced relapse after mean 8.1 months (5 to 15). Three patients died because of refractory autoimmune disease. Conclusions: Despite absence of marketing authorisation, rituximab is used to treat various refractory autoimmune diseases in daily rheumatological practice. This study showed good tolerance and short term clinical efficacy, with marked corticosteroid reduction in patients with SLE, pSS, vasculitis, and polymyositis.

UR - http://www.scopus.com/inward/record.url?scp=21144438589&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21144438589&partnerID=8YFLogxK

U2 - 10.1136/ard.2004.029694

DO - 10.1136/ard.2004.029694

M3 - Article

C2 - 15550531

AN - SCOPUS:21144438589

SN - 0003-4967

VL - 64

SP - 913

EP - 920

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

IS - 6

ER -

Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this